BSMA Radiopharma - Nuclear Medicine supply chain - working group
Join us for a collaborative working session leading to the launch of the Radiopharma & Nuclear Medicine Supply Chain Working Group.
The radiopharmaceutical field is moving fast, and the supply chain is now becoming part of the science.
We are seeing strong momentum around new therapeutic radionuclides, especially alpha emitters such as Ac-225, Pb-212 and At-211. These isotopes could support the next generation of targeted cancer treatments, including candidates designed to deliver radiation more precisely to tumour cells.
But “could” is the key word.
The clinical promise still needs to be confirmed with more data, larger trials and reproducible manufacturing. And this is where the challenge becomes very concrete: for several emerging isotopes, the number of qualified production sites, GMP manufacturing capabilities, transport routes and trained teams is still limited.
At-211 is a good example. It has attractive therapeutic properties, but its short half-life and specific production requirements mean that clinical development depends on having the right cyclotron capacity, radiochemistry, QC release, logistics and hospital connection in place. Without that network, it is difficult to generate the clinical evidence needed to move from promising science to scalable treatment.
In other words: innovation in radiopharmaceuticals is not only about discovering new molecules. It is also about building reliable isotope availability, regional manufacturing resilience and end-to-end supply chains that can support patients, hospitals and trials.
The field has enormous potential for oncology. But the next step will require alignment between research, production, regulation, logistics and clinical operations.
For supply chain specialists, this is one of the most interesting challenges in healthcare today: helping promising cancer drug candidates become real, accessible therapies.
Workshop Agenda
Welcome and introduction
Presentation of the theme and key issues
Identification of the main and most significant areas for collaboration
Discussion and roundtable